HBM Holdings-B (02142) spent HKD 322,300 to repurchase 110,000 shares on January 21.
Boehringer Ingelheim-B (02142) announced that the company invested HKD 322,300 on January 21, 2025.
HBM HOLDINGS-B (02142) announced that on January 21, 2025, the company repurchased 110,000 shares at a price of HK$2.93 per share, totaling HK$322,300.
On the same day, 26,000 ordinary shares were issued to meet the share incentive plan adopted and approved by the company shareholders on November 23, 2020.
Related Articles
China's first domestically developed original Bcl-2 inhibitor lisaftoclax is included in the new version of the National Reimbursement Drug List, as ASCENTAGE (06855) advances its dual-engine layout in parallel with global development.
Strong earnings growth supports the valuation floor, leaving room for a valuation recovery in undervalued Shenzhen Hans CNC Technology (03200)
Two new drugs enter medical insurance for the first time, one contract renewed, EVEREST MED (01952) accelerates its multi-product commercialization system.
China's first domestically developed original Bcl-2 inhibitor lisaftoclax is included in the new version of the National Reimbursement Drug List, as ASCENTAGE (06855) advances its dual-engine layout in parallel with global development.
Strong earnings growth supports the valuation floor, leaving room for a valuation recovery in undervalued Shenzhen Hans CNC Technology (03200)
Two new drugs enter medical insurance for the first time, one contract renewed, EVEREST MED (01952) accelerates its multi-product commercialization system.
